Skip to main content
SpringerLink
Log in

Window of opportunity for daclizumab

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

Interleukin-2 receptor-α (IL-2Rα) on antigen-presenting dendritic cells (DCs) is now shown to trans-present IL-2 to T cells during the earliest stages of T cell activation (604–609). The resulting T cell proliferation is blocked by daclizumab, an IL-2Rα–specific antibody used to treat multiple sclerosis and prevent transplant rejection, highlighting the importance of understanding individual variability in immune responses to daclizumab treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: DCs provide IL-2 to T cells via trans-presentation during the earliest steps of T cell activation.

Marina Corral

References

  1. Mottershead, M. & Neuberger, J. Expert Opin. Biol. Ther. 7, 1583–1596 (2007).

    Article  CAS  Google Scholar 

  2. Wang, H.M. & Smith, K.A. J. Exp. Med. 166, 1055–1069 (1987).

    Article  CAS  Google Scholar 

  3. Wuest, S.C. et al. Nat. Med. 17, 604–609 (2011).

    Article  CAS  Google Scholar 

  4. Bielekova, B. et al. Proc. Natl. Acad. Sci. USA 103, 5941–5946 (2006).

    Article  CAS  Google Scholar 

  5. Martin, J.F., Perry, J.S., Jakhete, N.R., Wang, X. & Bielekova, B. J. Immunol. 185, 1311–1320 (2010).

    Article  CAS  Google Scholar 

  6. Setoguchi, R., Hori, S., Takahashi, T. & Sakaguchi, S. J. Exp. Med. 201, 723–735 (2005).

    Article  CAS  Google Scholar 

  7. Velten, F.W., Rambow, F., Metharom, P. & Goerdt, S. Mol. Immunol. 44, 1544–1550 (2007).

    Article  CAS  Google Scholar 

  8. Dubois, S., Mariner, J., Waldmann, T.A. & Tagaya, Y. Immunity 17, 537–547 (2002).

    Article  CAS  Google Scholar 

  9. Granucci, F. et al. Nat. Immunol. 2, 882–888 (2001).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kimberly S. Schluns is in the Department of Immunology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.,

    Kimberly S Schluns

Authors
  1. Kimberly S Schluns
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kimberly S Schluns.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schluns, K. Window of opportunity for daclizumab. Nat Med 17, 545–547 (2011). https://doi.org/10.1038/nm0511-545

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0511-545

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation